Expression of HER2 in the eye and the potential for on-target side effects with antibody-drug conjugates

By afschroeder • May 8, 2026

Davenport S, Xie B, Hamblett K, Hausman D, Villalobos I, Singh HP, Cobrinik D, Hoon DSB, Zhou JY, Sibug-Saber M, Ma Y, Konecny GE, Heur M, Slamon DJ, Press MF. Expression of HER2 in the eye and the potential for on-target side effects with antibody-drug conjugates. Sci Rep. 2026 May 7. doi: 10.1038/s41598-026-51353-w. Epub ahead of print. PMID: 42098228.

Tags: Hematology/Oncology, Publications

Danvatirsen plus pembrolizumab versus pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma (PEMDA-HN): a randomized, phase 2 trial

Saba NF, Posner M, Harrington K, Neupane P, Rezaee R, Nenclares P, Jimeno A, Denker AE, MacIntyre S, Makris L, Wong D. Danvatirsen plus pembrolizumab[...]

Long-Term Survival After Percutaneous Image-Guided Thermal Ablation of Oligometastatic Renal Cell Carcinoma

Kim DH, Keshavarz P, Tibbe TD, Suh RD, Abtin F, Genshaft SJ, Drakaki A, Shuch BM, Pantuck AJ, Lu DS, Raman SS. Long-Term Survival After[...]

Real-World Toxicity and Efficacy Profile of Enfortumab Vedotin With or Without Pembrolizumab in Ultra-Elderly Patients With Advanced Urothelial Carcinoma

Mar N, Cabral MY, Go J, Kaakour D, Dwabe S, Seyedin SN, Drakaki A. Real-World Toxicity and Efficacy Profile of Enfortumab Vedotin With or Without[...]